Navigation Links
Cure for Hepatitis B

An Indian medicinal plant may be one of the most effective ways of treating disorders caused by the Hepatitis B virus, according to new research. Clinical trials using a drug based on the Keezhanali plant were conducted at the University of Madras in South India and the Scottish Centre// for Infection in Glasgow.

The results are believed to be better than any drug so far used to treat Hepatitis B - which is more than 100 times more infectious than HIV. Researchers say Keezhanali - or Phyllanthus Amarus to use its botanical name - stopped the Hepatitis B virus from multiplying and cleared up symptoms within a month in 30% of all cases they studied.

Hepatitis B is common in Asia, particularly in the sub-continent and China, and traditional Indian medical practice has long-standing methods for its treatment.

Dr S Thiagrajan, who began the research nearly two decades ago, says "This plant has been used conventionally in folklore medicine as a paste for treating jaundice cases. At that point of time, we had Hepatitis B as an easier viral model for studying in the lab. That is why we took it up and we had good convincing evidence by in-vitro studies that this plant extract is able to inactivate the virus," he added.

According to Dr Thiagranjan, the new drug scores over the two main drugs used to treat the virus - Lamuvidime and Interferon - because it is highly affordable and does not have the usual side-effects such as aches and pains and hair loss.The new drug is expected to be put on the Indian market by early next year, after which it will move to pharmaceutical counters around the world.


'"/>




Page: 1

Related medicine news :

1. Vitamin B for Hepatitis
2. Hepatitis G May Boost HIV Survival
3. Hepatitis E virus made impotent
4. Sharing injection equipment spreads Hepatitis C
5. Lymphomas Link to Hepatitis C
6. Hepatitis shots is promising
7. Need for Hepatitis Booster Questioned
8. Good News for HIV Patients Also Suffering From Hepatitis C Virus
9. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
10. The Effectiveness Of Hepatitis B Vaccine Questioned
11. New Treatment for Chronic Hepatitis B
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)... 2016  Parallax Health Sciences, Inc. ("Parallax" or the ... its pharmaceutical business, RoxSan Pharmacy, Inc. has received a ... all of the 42 states it is currently licensed ... Rashti Pharm . D, Pharmacist in Charge at RoxSan ... business. Medicare B spending last year came to roughly ...
(Date:12/5/2016)... 2016 Several leading Alzheimer,s disease experts will ... at 11 a.m. EST on December 6 in ... Trials for Alzheimer,s Disease (CTAD). The program will include ... and therapeutic targets that address deficient glucose metabolism observed ... failure of another therapy targeting the amyloid hypothesis, now ...
Breaking Medicine Technology: